Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,766 GBX | +2.11% | -0.65% | +21.81% |
05:01pm | US FDA approves Moderna's RSV vaccine, its second marketed product | RE |
05-30 | Goldman Sachs Starts GSK With Neutral Rating, $47 Price Target | MT |
Sales 2024 * | 31.64B 40.27B 3,164B | Sales 2025 * | 33.59B 42.76B 3,359B | Capitalization | 70.55B 89.8B 7,055B |
---|---|---|---|---|---|
Net income 2024 * | 5.56B 7.07B 556B | Net income 2025 * | 6.5B 8.28B 650B | EV / Sales 2024 * | 2.62 x |
Net Debt 2024 * | 12.39B 15.77B 1,239B | Net Debt 2025 * | 8.95B 11.39B 895B | EV / Sales 2025 * | 2.37 x |
P/E ratio 2024 * |
12.6
x | P/E ratio 2025 * |
10.9
x | Employees | 70,212 |
Yield 2024 * |
3.52% | Yield 2025 * |
3.64% | Free-Float | 94.54% |
Latest transcript on GSK plc
1 day | +2.11% | ||
1 week | -0.45% | ||
Current month | +5.59% | ||
1 month | +3.61% | ||
3 months | +5.92% | ||
6 months | +23.02% | ||
Current year | +21.81% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 30/04/10 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/23 |
James Ford
CMP | Compliance Officer | - | 31/07/95 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/23 |
Jonathan Symonds
CHM | Chairman | 66 | 31/08/19 |
Hal Barron
BRD | Director/Board Member | 62 | 31/12/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 17 M€ | +6.09% | - | |
2.51% | 7 M€ | +9.96% | - |
Date | Price | Change | Volume |
---|---|---|---|
31/05/24 | 1,766 | +2.11% | 16 170 874 |
30/05/24 | 1,730 | -0.94% | 8,017,940 |
29/05/24 | 1,746 | +0.37% | 10,002,350 |
28/05/24 | 1,740 | -1.94% | 4,684,441 |
24/05/24 | 1,774 | -0.20% | 4,163,301 |
Delayed Quote London S.E., May 31, 2024 at 04:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.81% | 89.9B | |
+39.94% | 734B | |
+32.83% | 591B | |
-6.04% | 350B | |
+14.91% | 315B | |
+1.81% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+5.91% | 161B |
- Stock Market
- Equities
- GSK Stock